Table Of Content

Maturitas, 15 (1992) 265 Elsevier Scientific Publishers Ireland Ltd. Author Index Volume 15 Alvarez del Buergo, M., 233 Garde, K., 7 Nilsson, K., 121 Ayalon, D., 25 Gerbaldo, D., 199 Nilsson, S., 209 Gonzalez-Merlo, J., 113 Bachmann, G.A., 3 Obel, E.B., 61 Backe, B., 183 Hammer, M., 71 Oddens, B.J., 171 Baracchini, P., 199 Hanes, V., 53 Berg, G., 71 Heimer, G., 121 Parazzini, F., 141 Bernardini, L., 199 Hernandez, E.R., 233 Pecchio, F., 47 Boulet, M.J., 171 Heytmanek, G., 53 Pescetto, G., 199 Byrjalsen, I., 39 Hotz, E., 195 Pouilles, J.M., 217 Hunskaar, S., 183 Pryse-Davies, J., 71 Capelli, N., 225 Castelo-Branco, C., 113 Imthurn, B., 195 Rekers, H., 101 Christiansen, C., 39 Isaia, G., 47 Revilla, M., 233 Clausen, H.V., 241 Ribot, C., 217 Coope, J., 151 Jensen, L.C., 61 Rico, H., 233 Crona, N., 209 Riis, B.J., 39 Keller, P.J., 195 Riphagen, F., 101 Darj, E., 209 Kopera, H., 1 Risberg, B., 71 de Cecco, L., 199 De Cooman, S., 17 La Vecchia, C., 141 Sciolla, A., 47 de Deuxchaisnes, C.N., 17 Larsen, L.G., 241 Sitruk-Ware, R., 129 Devogelaer, J.P., 17 Lehert, P., 171 Solstad, K., 7 di Stefano, M., 47 Limor, R., 25 Spinetti, A., 225 Drogenijk, A.C., 101 Lindgren, R., 71 Statter, M., 25 Duran, M., 113 Lindhard, A., 61 Steendahl, E., 61 Loft, A., 241 Steinberg, R., 25 Eckstein, N., 25 Eshel, A., 25 Marsh, J., 151 Taponeco, F., 225 Melis, G.B., 225 Thormann, L., 39 Feinstein, Y., 25 Metka, M., 53 Tremollieres, F., 217 Felding, C., 241 Meuwissen, J.H.J., 33 Ferraiolo, A., 199 Mikkelsen, A.L., 241 Vagman, I., 25 Fink, B., 61 Molinatti, G.M., 47 Valkenburg, H.A., 101 Fioretti, P., 225 Moret, E., 33 van Langen, H., 33 Foldes, J., 25 Mussetta, M., 47 Villa, L.F., 233 Fulcheri, E., 199 Visser, A.P., 171 Navarro-Morquecho, I., 33 Negri, E., 141 Gambacciani, M., 225 Maturitas, 15 (1992) 267-269 Elsevier Scientific Publishers Ireland Ltd. Subject Index Volume 15 Abrasio, oestrogen/progestogen therapy, curet- Combined transdermal therapeutic systems, tage, menopause, vaccuum aspiration, 61 menopause, hormone replacement therapy, Age, oestrogens, skin, collagen, menopause, 113 195 Androgen decline, male climacteric, middle-aged Compliance, hormone replacement therapy, men, climacteric, midlife crisis, climacteric general practice, 151 myths, 7 Continuous regimen, hormone replacement Androgen therapy, male hypogonadism, bone therapy, oestradiol valerate, cyproterone mass, osteodensitometry, 17 acetate, lipid metabolism, postmenopause, 53 Attitude to health, menopause, oestrogens, hor- Curettage, oestrogen/progestogen _ therapy, mone replacement therapy, 183 menopause, abrasio, vaccuum aspiration, 61 Cyproterone acetate, hormone replacement Bleeding patterns, placental protein 14, hormone therapy, continuous regimen, oestradiol replacement therapy, endometrial response, valerate, lipid metabolism, postmenopause, 39 53 Bone densitometry, menopause, bone mass, bone mineral content, 233 Endometrial response, placental protein 14, hor- Bone mass, male hypogonadism, osteoden- mone replacement therapy, bleeding patterns, sitometry, androgen therapy, 17 39 Bone mass, menopause, bone mineral content, Endometrium, hormonal replacement therapy, bone densitometry, 233 hysteroscopy, hyperplasia, 199 Bone metabolism, GnRH-analogue treatment, Endometrium, transdermal, estrogen, gestagen, safety aspects, calcium homeostasis, 25 hyperplasia, 71 Bone mineral content, male hypogonadism, Endometrium, vaginosonography, oestrogen calcitonin, testosterone, bone tissue, 47 replacement therapy, 33 Bone mineral content, menopause, bone mass, Epidemiology, estrogens, progestins, breast bone densitometry, 233 cancer, 129 Bone tissue, male hypogonadism, bone mineral Estrogen, transdermal, gestagen, endometrium, content, calcitonin, testosterone, 47 hyperplasia, 71 Breast cancer, estrogens, progestins, epidemi- Estrogens, progestins, breast cancer, epidemiology, 129 ology, 129 Calcitonin, male hypogonadism, bone mineral General practice, hormone replacement therapy, content, testosterone, bone tissue, 47 compliance, 151 Calcitonin, osteoporosis, ovariectomy, preven- Genital prolapse, oestradiol, 241 tion, 225 Genito-urinary tract, menopause, incontinence, Calcium homeostasis, GnRH-analogue treat- 101 ment, safety aspects, bone metabolism, 25 Gestagen, transdermal, estrogen, endometrium, Climacteric myths, male climacteric, middle-aged hyperplasia, 71 men, climacteric, androgen decline, midlife GnRH-analogue treatment, safety aspects, bone crisis, 7 metabolism, calcium homeostasis, 25 Climacteric, male climacteric, middle-aged men, androgen decline, midlife crisis, climacteric Hormonal replacement therapy, endometrium, myths, 7 hysteroscopy, hyperplasia, 199 Clinical trial, hysterectomy, perimenopausal, 3 Hormone replacement therapy, compliance, Collagen, oestrogens, skin, age, menopause, 113 general practice, 151 268 Hormone replacement therapy, continuous Menopause, oestrogens, skin, collagen, age, 113 regimen, oestradiol valerate, cyproterone Menopause, risk factors, reproductive factors, acetate, lipid metabolism, postmenopause, 53 141 Hormone replacement therapy, menopause, Middle-aged men, male climacteric, climacteric, combined transdermal therapeutic systems, androgen decline, midlife crisis, climacteric 195 myths, 7 Hormone replacement therapy, menopause, Midlife crisis, male climacteric, middle-aged oestrogens, attitude to health, 183 men, climacteric, androgen decline, climac- Hormone replacement therapy, non-hormonal teric myths, 7 treatment, tranquillizers, reported use, inter- country variation, 171 Non-hormonal treatment, hormone replacement Hormone replacement therapy, placental protein therapy, tranquillizers, reported use, inter- 14, endometrial response, bleeding patterns, country variation, 171 39 Hyperplasia, endometrium, hormonal replacement therapy, hysteroscopy, 199 Oestradiol valerate, hormone replacement Hyperplasia, transdermal, estrogen, gestagen, therapy, continuous regimen, cyproterone endometrium, 71 acetate, lipid metabolism, postmenopause, 53 Hysterectomy, perimenopausal, clinical trial, 3 Oestradiol, genital prolapse, 241 Hysteroscopy, endometrium, hormonal replace- Oestrogen replacement therapy, vaginosono- ment therapy, hyperplasia, 199 graphy, endometrium, 33 Oestrogen/progestogen therapy, curettage, Incontinence, menopause, genito-urinary tract, menopause, abrasio, vaccuum aspiration, 61 101 Oestrogens, menopause, attitude to health, hor- Inter-country variation, hormone replacement mone replacement therapy, 183 therapy, non-hormonal treatment, tran- Oestrogens, skin, collagen, age, menopause, 113 quillizers, reported use, 171 Oral hormone replacement therapy, osteoporosis, prevention, 217 Osteodensitometry, male hypogonadism, bone Lipid metabolism, hormone _ replacement therapy, continuous regimen, oestradiol mass, androgen therapy, 17 valerate, cyproterone acetate, postmeno- Osteoporosis, ovariectomy, calcitonin, preven- pause, 53 tion, 225 Lipids, progesterone, postmenopausal, lipopro- Osteoporosis, prevention, oral hormone replace- teins, 209 ment therapy, 217 Lipoproteins, progesterone, postmenopausal, Ovariectomy, osteoporosis, calcitonin, preven- lipids, 209 tion, 225 Low-dose oestradiol, postmenopausal, vaginal atrophy, 121 Perimenopausal, hysterectomy, clinical trial, 3 Placental protein 14, hormone replacement Male climacteric, middle-aged men, climacteric, therapy, endometrial response, bleeding pat- androgen decline, midlife crisis, climacteric terns, 39 myths, 7 Postmenopausal, low-dose oestradiol, vaginal Male hypogonadism, bone mass, osteoden- atrophy, 121 sitometry, androgen therapy, 17 Postmenopausal, progesterone, lipids, lipopro- Male hypogonadism, bone mineral content, teins, 209 calcitonin, testosterone, bone tissue, 47 Postmenopause, hormone replacement therapy, Menopause, bone mass, bone mineral content, continuous regimen, oestradiol valerate, bone densitometry, 233 cyproterone acetate, lipid metabolism, 53 Menopause, hormone replacement therapy, com- Prevention, osteoporosis, oral hormone replace- bined transdermal therapeutic systems, 195 ment therapy, 217 Menopause, incontinence, genito-urinary tract, Prevention, osteoporosis, ovariectomy, 101 calcitonin, 225 Menopause, oestrogen/progestogen _ therapy, Progesterone, postmenopausal, lipids, lipopro- curettage, abrasio, vaccuum aspiration, 61 teins, 209 Menopause, oestrogens, attitude to health, hor- Progestins, estrogens, breast cancer, epidemi- mone replacement therapy, 183 ology, 129 269 Reported use, hormone replacement therapy, Testosterone, male hypogonadism, bone mineral non-hormonal treatment, tranquillizers, content, calcitonin, bone tissue, 47 inter-country variation, 171 Tranquillizers, hormone replacement therapy, Reproductive factors, menopause, risk factors, non-hormonal treatment, reported use, inter- 141 country variation, i71 Risk factors, menopause, reproductive factors, Transdermal, estrogen, gestagen, endometrium, 141 hyperplasia, 71 Vaginal trophy, low-dose oestradiol, Safety aspects, GnRH-analogue treatment, bone postmenopausal, 121 metabolism, calcium homeostasis, 25 Vaginosonography, endometrium, oestrogen Skin, oestrogens, collagen, age, menopause, 113 replacement therapy, 33